Index

abortion by medical methods 176, 177
‘absorption’ barriers in skin 392
absorption, distribution, metabolism and administration (ADME) 139
academic community 70, 119, 125, 323
access to nanotechnology 78, 88, 91–4, 389, 390
accountability and accreditation by third parties 150, 157
accuracy of information 345
Action Group on Erosion, Technology and Concentration (ETC) 364
Action Plan (European Community) 268
advances in health and medicine 113
advocacy groups 155
aerosols 144
government agreement on language terms, international 347
agricultural chemicals 214, 225, 252
certification 135, 158
demand for 99
air pollution 152, 193, 271
legislation 230
Air Quality (England) Regulations 2000 230
airborne particulates, inhaled 134, 143
alteration by production 136
American National Standards Institute (ANSI) 358
animals 140, 141, 166, 179, 198, 325
anthropogenic chemicals 138
anthropomorphism and animism 42, 43
Antigua, online gambling services 310–14
applications of nanomaterials 227, 236
using NT-components 80
arms and army 33, 113, 274
artificial intelligence 265
asbestos 6–7, 115, 134
Australian case 128
health damages 267
known toxic 193
nanoparticles and 271
regulatory history 21
Asia Pacific Laboratory Accreditation Cooperation 366
Asia-Pacific Economic Cooperation (APEC) 342
assessment before mass production in EU 270
asteroid collisions 154
ASTM International (US standards) 345, 349
atoms 3, 149, 336
auditing firms and procedures 157, 158, 300
Australia, nanotechnology regulation in 166–84, 256
public debates 126
authority of the state 151
awareness raising in Europe 278
Barbuda, online gambling services 310–14
barter and trade 33
behavioural requirement 200
benefits 88, 96–100, 390
and dangers 34
and risks 82, 83
‘best practice’ guidelines 364
biocides (dangerous substances) 231
bio-computational models 142
bioengineered foods in US 124–5
biological membranes, permeation of 256
biological mode of action 195, 197, 200
biological sciences, metrology in 333
biomedical science 240
biomonitoring 143
biotechnology 37, 49, 57, 123, 168, 320 concerns 287
regulatory regimes 354
in US 189, 190, 191 revolution 95
Biotechnology Science Coordinating Committee (BSCC) 190
bird flu pandemics 154
blindness, overcoming 58
bloodstream 144
‘bottom-up’ approach, for standards 348, 349
bovine spongiform encephalopathy (BSE) 124, 126
brain tissue, damage to 257
brain-to-brain communication 58
Brazil, heavy investment 90–91
British Standards Institution (BSI) 235, 358
technical committee 275
bureaucracy in European Union 279
business conduct, responsible 156
ethics 78
initiatives 276–7

Cameras with neural nets 57
cancer 134
treatment 71
Candela (luminous intensity) measurement 337
capitalism 98, 153
car paints 67
carbon nanotubes (CNTs) 4, 136, 143
carcinogens in food law 201–2
cardiovascular disease 134, 138
case studies of success or failure 122
causal relationships 122, 139
cell phones 36
Center for Responsible Nanotechnology 203
certification agencies 300
characterization 344
protocols for nanoparticulates 347
Chemical Abstract Service (CAS) number 327
chemical content and control 224, 323
chemical entities, new 137
chemical industry, dispute, US 207
chemical levels in air, food and water 143
chemical mode of action 195, 197, 200
chemical purity 347
chemical regulatory scheme 136, 253
Australia 249–53
chemical safety and OECD 322–3
chemical sciences, metrology in 333
chemical substances 291
disposal 218
‘existing’ and ‘new’ 134, 199, 254
chemicals 271, 272
and adverse health effect 139
in cosmetics 136
management systems 328
manufacture 222
nanotechnology products, Australia 239–60
Chemicals Programme (OECD) 327
regulation 391
testing, guidelines 140
chemistry 4, 271, 320
childhood and animism 42
child pornogaphy 63, 152
China 90–91, 95, 101
R&D and commercialization 365
chips for computers 36
Cientifica 277
citizens
and consumers 44
as ‘guinea pigs’ 18, 123
citizenship and rights 93
civil interest society groups 332
civil liberties 15, 16, 168
civil regulation 151, 155, 158
civil society groups 149, 364
influence 374
claims from new technologies 7
clarity, increased 74
classification of nanomaterials 146
clean air acts 150
clean drinking water, access 99
clean energy 67, 70
clean water 52
Clean Water Act (US) 203
climate change 154
public anxiety 333
‘climate levy’ (EU) on products from non-Kyoto states 287
clinical definitions 13
cloning 168
coatings 214
and pigments 224
codes of good conduct 159
cognitive research 41, 49, 57, 168
Colipa, research on cosmetics 276
combustion exhaust 271
‘command and control’ (CAC) regulation 354
commercial production, regulations for 222
commercialization 6, 78, 113, 159, 249
of nano-products 253
common environmental norms 301
common understanding 30, 60, 74, 113
communication 56, 59
encouragement of 269
public 279
technologies 69
community backlash 145
community law, supremacy 298
compensation 63
competition, unfair 278
competitive markets 96
compliance costs 393
computer ethics 49, 51, 52, 53
conceptual frameworks 14–18
consensus decisions 206
construction materials 214, 224
Construction Products Directive (CPD) 224
consultant networks 119
consumers
products 73, 212, 235
protection 71, 365
regulations for use 226
contaminants 135
of environment 138
control 88, 100–103
divide 389
groups 120
in scientific research 50, 55
of technologies 51, 168
Control of Major Accident Hazard Regulations 229
co-operation 360
between trade and regulatory community 297
Coordinated Framework for Regulation of Biotechnology (US) 190, 191
co-regulation 158
corn (bacillus thuringiensis resistant) 191
cosmetics, 212, 214, 224, 270, 276
Australia 253–6
importation into 255
nanotechnology products 239–60
regulation 195
zinc oxide 144
cost/benefit analysis 50, 55
cost regulation 157
Council of the European Union 266
criminal liabilities and sanctions 151, 158
crisis of confidence in science 126
cubit, Pharaoh’s arm 335
cultural horizon 36–8
cultural norms and values 387
customs duties 316
daily intake 143
damage potential of nanoparticles 5, 198
dangerous substances 76, 300
accidents 229
data 56–7, 71
Database on Human Health and Environmental Safety Research 331
data-reporting requirement 210
debt-rating agencies 158
decimal metric system 336
decision-making 111
decentralization 98
Dedalus, and the Labyrinth 31
Defense Advanced Research Projects Agency (DARPA) 58, 93
defence, death of 154
defibrillators 58
definitions 347, 360
of nanotechnology 10, 11, 12, 200–201
degree of acceptable noise 157
degree of violence 157
Delaney Clause 1958, US 201–2
democracy and citizen participation 181
dendrimer technology 243
Department for Environment, Food and Rural Affairs (DEFRA) (UK) 74
regulatory assessment 213, 214–17
task force 272
deregulation of nanotechnology 161
dermal ingestion 143, 144
dermatology 257
designers of goods 94
detergents 214, 224
developed countries
economic and social advancement 168
developing countries
impact on 74
and technical regulations 339
development, determination of 101
dialogue of science and industry 68–72
dialogue sessions, moderated 75
dictation by nanotechnologists 181
dimensional measurements 342
direct exposure monitoring 143
disabled people 57
discrimination 290
diseases 33, 57, 97
disposal of nanomaterials 236, 249
dispute settlement mechanism of WTO 291, 292, 298, 299
disruptions, economic, to agriculture 168
dissemination of information 360
distribution of access 92
DNA ‘fingerprinting’ 57
documentary standards 339–40
for nanotechnology 344–5
domestic policy 295
autonomy 287, 316
harmonization 299
domestic regulation 160, 310
domination by large corporations 94–5
dose metrics 134, 233
dose response relationship 138, 139, 141–2
drinking water pipes, interior coating 214
drugs 61, 67, 175–7, 370
duplication avoidance 323, 325, 329
eyearly stage process for safety 321–2
echolocation of bats 59
European Court of Justice 296, 297
eco-label criteria 300, 301
ecological risks 152
econometric analysis 122
economic aspects 76, 78
disruption 55
EU research on 269–70
gains 353
ecototoxicity 344
electrical and electronic products 214, 225, 350, 390
electrical conductivity 4
electron microscope 342
electronics 75, 97
embryonic stem cell research 239, 240
emerging technologies, evaluation 364
emissions 222
to air and water 229
assessment of levels 227, 228
of nanomaterials 236
Emission Limit Values (ELVs) 222, 227, 228
energy conversion and storage 3, 75, 76
engineering 4
nanoparticles 366
research 362
environment 268, 346
degradation, public anxiety 333
emissions 219
exposure standards 135
group resistance 195
harm 169, 234
health 96, 137, 323
issues of gene technology 172, 173, 174
preservation 52
protection in other Member States 297
regulatory gaps 213
Environment Assessment Levels 228
Environmental Defence (ED) (US) 207
environmental impact 20, 213, 226, 232–4, 293
environmental law, US 15, 16, 208
Environmental Law Institute (ELI) 4
environmental non-governmental organizations (NGOs), experts 323
environmental problems, pressing 303
<table>
<thead>
<tr>
<th>Index</th>
<th>411</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental Protection Agency, (EPA) (US) 189, 200, 306</td>
<td></td>
</tr>
<tr>
<td>environmental risks 78, 223, 224, 233</td>
<td></td>
</tr>
<tr>
<td>epidemics 33</td>
<td></td>
</tr>
<tr>
<td>epidemiological studies 365</td>
<td></td>
</tr>
<tr>
<td>ethical and socio-economic (ESE) concerns, Australia 166–8, 173–81</td>
<td></td>
</tr>
<tr>
<td>ethical, legal and social applications (ELSA) 68, 69, 74–7</td>
<td></td>
</tr>
<tr>
<td>ethical issues 6, 49, 166–84, 205, 388</td>
<td></td>
</tr>
<tr>
<td>of gene technology 171–2, 173, 174</td>
<td></td>
</tr>
<tr>
<td>ethical uncertainties 113, 391</td>
<td></td>
</tr>
<tr>
<td>ethics 51–4, 73, 78, 268</td>
<td></td>
</tr>
<tr>
<td>ethnic discrimination 152</td>
<td></td>
</tr>
<tr>
<td>Eucomed 276</td>
<td></td>
</tr>
<tr>
<td>EurepGAP, agricultural products 158</td>
<td></td>
</tr>
<tr>
<td>European Action Plan on nanotechnology 266</td>
<td></td>
</tr>
<tr>
<td>European Commission 266–71</td>
<td></td>
</tr>
<tr>
<td>European Court of Justice (ECJ) 288</td>
<td></td>
</tr>
<tr>
<td>European Directives 223</td>
<td></td>
</tr>
<tr>
<td>European Economic Community treaty 296</td>
<td></td>
</tr>
<tr>
<td>European Environmental Agency 271</td>
<td></td>
</tr>
<tr>
<td>European initiatives 72–4</td>
<td></td>
</tr>
<tr>
<td>European metrology institutes 275</td>
<td></td>
</tr>
<tr>
<td>European Nanobusiness Association 276</td>
<td></td>
</tr>
<tr>
<td>European nanotechnology community 265–81</td>
<td></td>
</tr>
<tr>
<td>European Parliament and nanotechnology 266–7</td>
<td></td>
</tr>
<tr>
<td>on voluntary agreements 302</td>
<td></td>
</tr>
<tr>
<td>European Patent Organisation 278</td>
<td></td>
</tr>
<tr>
<td>European perspective 68</td>
<td></td>
</tr>
<tr>
<td>European research 70, 266</td>
<td></td>
</tr>
<tr>
<td>European strategy for nanotechnology 269</td>
<td></td>
</tr>
<tr>
<td>European Union (EU) 104 approach to trade and regulation 296–8</td>
<td></td>
</tr>
<tr>
<td>directives on waste management 231 documentation 279</td>
<td></td>
</tr>
<tr>
<td>GMO case 315–16</td>
<td></td>
</tr>
<tr>
<td>legislation 229–231</td>
<td></td>
</tr>
<tr>
<td>inadequacies 232</td>
<td></td>
</tr>
<tr>
<td>member states and unilateral initiatives 297</td>
<td></td>
</tr>
<tr>
<td>metrology 274–6</td>
<td></td>
</tr>
<tr>
<td>policymaking 266</td>
<td></td>
</tr>
<tr>
<td>public sector investor 373</td>
<td></td>
</tr>
<tr>
<td>research policies 269–72</td>
<td></td>
</tr>
<tr>
<td>technical research 270–72</td>
<td></td>
</tr>
<tr>
<td>Europe, national policies 272–4</td>
<td></td>
</tr>
<tr>
<td>evaluation 111, 119–22, 300, 321</td>
<td></td>
</tr>
<tr>
<td>exemptions 214</td>
<td></td>
</tr>
<tr>
<td>exit regulation 157</td>
<td></td>
</tr>
<tr>
<td>experts 323</td>
<td></td>
</tr>
<tr>
<td>interviews with 75</td>
<td></td>
</tr>
<tr>
<td>trusting of 154</td>
<td></td>
</tr>
<tr>
<td>explosives 214, 225, 229</td>
<td></td>
</tr>
<tr>
<td>exposure 234</td>
<td></td>
</tr>
<tr>
<td>assessments 138, 139, 142–4, 233, 236</td>
<td></td>
</tr>
<tr>
<td>detection in environment and workplace 330</td>
<td></td>
</tr>
<tr>
<td>determination 348</td>
<td></td>
</tr>
<tr>
<td>of nanomaterials 233</td>
<td></td>
</tr>
<tr>
<td>famine 89, 97</td>
<td></td>
</tr>
<tr>
<td>farmers opposed to GM crops 170–74</td>
<td></td>
</tr>
<tr>
<td>fatality to humans 152</td>
<td></td>
</tr>
<tr>
<td>fear 154, 393</td>
<td></td>
</tr>
<tr>
<td>of nanotechnology 40</td>
<td></td>
</tr>
<tr>
<td>feeding the world 98</td>
<td></td>
</tr>
<tr>
<td>financial implications 158, 168</td>
<td></td>
</tr>
<tr>
<td>fine dust air pollution 273</td>
<td></td>
</tr>
<tr>
<td>fire 229</td>
<td></td>
</tr>
<tr>
<td>Flemish Parliament 273</td>
<td></td>
</tr>
<tr>
<td>flexibility of regulatory framework 241</td>
<td></td>
</tr>
<tr>
<td>food additives 135</td>
<td></td>
</tr>
<tr>
<td>Food and Drug Administration (FDA) (US) 189, 192, 195–7</td>
<td></td>
</tr>
<tr>
<td>food from cloned animals 179</td>
<td></td>
</tr>
<tr>
<td>and feed regulation 294</td>
<td></td>
</tr>
<tr>
<td>and food packaging 76, 236, 242</td>
<td></td>
</tr>
<tr>
<td>industry and nanotechnology 252</td>
<td></td>
</tr>
<tr>
<td>food contaminants, regulation 135</td>
<td></td>
</tr>
<tr>
<td>food processing 214, 225</td>
<td></td>
</tr>
<tr>
<td>food regulation 177–81, 195</td>
<td></td>
</tr>
<tr>
<td>food safety 126, 150</td>
<td></td>
</tr>
<tr>
<td>Food Standards Agency (FSA) (UK) 213, 272</td>
<td></td>
</tr>
<tr>
<td>Food Standards Australia New Zealand (FSANZ) 178, 179, 252</td>
<td></td>
</tr>
<tr>
<td>foreign imports 290</td>
<td></td>
</tr>
<tr>
<td>foresight, lack of 214</td>
<td></td>
</tr>
<tr>
<td>France, prospectives and social actions 273</td>
<td></td>
</tr>
</tbody>
</table>
Index

‘frankenfoods’ 71
freedom in scientific research 50
free trade 287
and regulatory ambitions 287
technical standards and 274
French asbestos ban 307–8
French Standards Association 276
Friends of the Earth (FoE) 364
on failure of regulation 256
on nano-specific regulations 247–8
on need for nano-research 259
on sunscreens 197
fuel catalysts and additive 212, 214
fuel cells and batteries 214, 225
funding
for nanotechnology 67
lack of, US 207
programmes 206
research and development (R&D) 239

gambling and betting services 310–14
gaps
in knowledge 268
in regulatory frameworks 137, 145
in UK 272
gastrointestinal tract 392
General Agreement on Tariffs and Trade (GATT) 289–92
and trade liberalization 298
General Agreement on Trade in Services (GATS) 289, 310
General Product Safety Directive (GPSD) 223
gene technology 166, 168, 180, 181
regulatory scheme 170–74
Australia 169–75
Gene Technology Act 2000 (GT Act) (Australia) 169, 170
Gene Technology Ethics Committee (GTEC) (Australia) 171, 172
Gene Technology Regulator (GTR) (Australia) 170–72
genetically modified (GM) crops 70, 166, 320
moratoriums, Australia 178, 179, 180
opposition to, in UK126
public anxiety 333

genetically modified organisms (GMOs) 119
Australia 170–73
debate in Europe 124
EU’s regulatory regime 292
genetically modified (GM) foods 7, 173, 205
non-admittance in Europe 267
genetic engineering 124, 265, 268
genetic knowledge 277–8
genetic profiles 57
genocide 5
German Office of Technology Assessment (TAB) 272–3
Germany 73, 126, 275–6
glass, self-cleaning 212
global and national regulatory response 149
global energy needs 52
global harmonization of legal metrology 338
global intellectual property market, initiatives 368
globalization of markets 356–8, 371, 372
Global Positioning Systems (GPS) 56
GMOs see genetically modified organisms
Good Agricultural Practices (GAP) 158
Good Laboratory Practice (GLP) 325
good practice 346
governance of nanotechnology 149–63
government 9, 122
and business contracts 115
dialogue 19
expenditure 353, 354
licensing 8
policy 111, 117, 207–8
and public interest 111
‘green’ labels 158
Green Party 266
Greenpeace 69, 70, 125, 266, 364
Greenpeace Environmental Trust 76
green political power 124
Green Revolution 98

harm to human health 169
harmonization 288, 300, 301, 303
nanotechnology 293
negative 288, 292
hazard assessments 199, 233
hazard identification 138, 139, 236
hazard of nanomaterials 233
Hazardous Materials and Waste Management 358
hazardous metals 294
health 74, 113, 268, 346, 372
health and safety 137, 212, 366, 370
for workers 197–9, 219
Health and Safety Executive (HSE) (UK) 213
health and sickness 57
health impacts 20, 73, 137–45, 152, 270
of asbestos 138
of gene technology 172, 173, 174
of nanotechnologies 293
unique to nanomaterials 196
health/sanitary inspections in exporting Member States 298
health-threatening pollutants 230
hearing, enhanced 59
hepatotoxicity 140
‘home country control’ 307
homogeneity among EU members 298
hormones 308–10
hormone-treated meat 308
humans
anatomy 335
cloning 166, 240, 241
communication 39
embryo research 176, 177, 241
enhancement 57–62, 390
genome project 68–9
health 79, 389
and environment 270–72
hazard 78, 234
human experience, outside of 40
Human Health Risk Assessment (HHRA) 134–46, 391
human interaction, complexity of 37
human life, sanctity of 240
humanity’s interaction with nature 151
human-machine interactions 43, 168
hybrid regulation 151, 161
identification 329–30, 360
of gaps in knowledge 344
of waste nanomaterials 232
ignorance and guilt 125
illness caused by bathroom cleaning substance 204
immunotoxicity 140
Impart project, EC-funded 270
impediments to trade 321
importation of cosmetics in Australia 255
incineration 231, 232
India 95–91, 101
indifference and ignorance 267
individual and sectionals 114
Industrial Chemicals (Notification and Assessment) Act 1989 253–4
industrial chemicals 249
industrial emissions 226–32
industrial initiatives 276–7
industries 332
and environmental groups 206–7
participation in voluntary programs 195
proactive approach 236
and risk research 280
role of 301–3
self-regulation 207–8
inequalities 87–8, 92, 93, 98, 99, 390
information about individuals 56
and communication technologies (ICT) 79
dissemination 331
sciences 168
sharing 331, 360
technology 35–7, 49, 57, 95
‘informed consent’ for consumers 258
infrastructure, coherent system 269
inhalation 134, 143, 348
injury to humans 152
innovation and regulation balance 206
Institute of Nanotechnology (UK) 356
insurance 69, 268, 277, 356
Integrated Pollution Prevention and Control (IPPC Directive) 219–22, 226
integrity of evaluations and markets 123, 126
intellectual property (IP) 52, 268, 277–78, 367–72
laws, changes 61
owners, and profit 94
regulatory regimes 96, 354
intellectual property rights (IPRs) 60, 61 278, 299, 367
international cooperation 268, 321, 365, 385
international dialogue on responsible research and development of nanotechnology (IDRRDN) 361
international electrotechnical committee (IEC) 339
international harmonization, OECD 301, 324
international measurement system 333, 336–40
international organization for standardization (ISO) 14, 142, 235, 359
international organization of legal metrology (OILM) 338
international programme on chemical safety (IPCS) 140
international regulation 104, 287–8, 355–65, 367–72
international risk governance council (IRGC) 277, 364
international standards organization (ISO) 104, 229, 289, 334, 339, 355
liaisons with relevant organisations 350
national delegations 349
technical committee for nanotechnologies 345–50
international system of units (SI) 337, 339
international telecommunications union 339
international trade 288–96, 295, 304, 372
interpretation of definitions 227
in vitro and in vivo studies 141, 142, 144, 239
IPPC see integrated pollution prevention and control
ISO/TC see international standards organization/technical committee
issue identification 138, 139
james hardie case, australia 128
Japan
public sector investor 373
R&D and commercialization 365
jobs for humans, replacement by machines 169
Kelvin (temperature) measurement 337
knowledge
adequate funding for 145
dissemination 31, 268
gaps 219, 232
and legislation 280
risks and uses 198
labelling laws 113, 236, 258, 259
language and public policy 112
legality
aspects 55, 76–9
basis for ethical/social concerns 205
implications, EU research on 269–70
inertia and vulnerability in US 191, 201–3, 208
metrology 338
penalties 158
rules and sanctions 150, 151, 354
Leghold trap regulation 297
legislation
and definition of properties 236
outdated in US 201–3
slow-moving 204
legitimization of policies 122
liability 79, 103, 389
life cycle analysis 301
life-sciences 75
low wage countries 287
lubricants 214
lungs 144
asbestos, cancer causing agent 138
cancer 140
damage to 257
magic nano bathroom cleaner 204, 274
magna carta 335
magnetic nanomaterials 212
major incidents in US, legal stimulation 208
malformed babies 267
malsch technovaluation 277
management performance 121
manipulation of matter at atomic scale 3, 4, 239
manufactured nanomaterials 327–32
manufacturing, state-of-the-art 94, 95
mapping of current literature 75
Marine Mammal Protection Act (MMPA) 304–5
marketability and public acceptance 166
market power, Japan, US and EU 370, 371
markets 158
  conditions for farmers 170, 171
  expansion 34
  potential 70
  unconstrained entry, 353
material standards 35, 96, 103
measurement 333–6
  and characterization 346
  and testing 274–5
  uncertainty 342–3
mechanical mode of action 195, 197, 200
media 125
medicine 35, 75
  applications 55, 214, 225
  devices 195, 268
  diagnosis 3, 76, 79
  ethics 78
  implants 281
  toxicity 344
mental images 42
metal oxide particle 343
metals 231
meta-regulation 159
Metre Convention 336
Metre-Kilogram-Second (MKS) system 336
metrological infrastructure 341
metrology 234, 274, 333–51
  and advanced development 340
  terms in 334
metrology tools, need for 342, 344
Mexico, tuna imports from 304–5
microbiological limits 252
military applications 9, 98, 168, 274
military nanotechnologies, access 93
military purposes, use for 5, 59, 71
miniaturization 35, 390
molecular composite materials 242
molecular configuration of chemicals 3, 327
molecular manufacturing 5, 55
molecular nanosystems 203
monitoring methods, validated 56, 228, 233
moral considerations, Australia 175, 176, 178
moratorium
  on GM techniques and marketing 8, 315
  on nanotechnology 50, 128, 166, 167, 364
  on non-medical implants 274
most favoured nation principle 290, 316
multi-component system 196–7
multidisciplinary technology 68, 74, 145
multi-faceted role of state 370
multilateral environmental and trade agreements 292, 300, 372
mutual acceptance of data (MAD) system 324–7
mutual recognition 300, 324
nano-capsules 253
Nanocare project, health risks of nanoparticles 276
nanocomposites 347
nanodivides 104–5, 390
nanoelectronics 56
nanoethics 49–64
Nanoforum 277
Nanojury UK 74
Nanology project (EC) 68, 75, 76, 389
nanomachines 242
nanomaterials 137, 232, 347
nanomedicine 268
nano-metaphors in science and technology 41, 44
nanometrology 275, 333, 341–3
nanoparticles 212, 213, 257, 344, 347
nanorobots 35, 71, 388
nanoscale circuits 36
nanoscale coatings 347
nano-scale films 212
Nanoscale Materials Voluntary Program (NVP) 195
nano-sized particles in approved drugs 204
  assessment companies 277
Index

and ethical and socio-economic (ESE) concerns, Australia 179–81
industry, and risk governance 235, 236
lack of new laws for 303
prevention 274
priority research area, Australia 242–6
regulation 111–29, 189–210
risks 123, 160, 209
as single or multiple topic 200
terminology 10, 11, 12, 349
nanotechnology-and-health in Europe 268
Nanotechnology and Research Act (US) 206
Nanotechnology Engagement Group (NEG) (UK) 235, 273
Nanotechnology Research Coordination Group (NRCG) (UK) 234
nanotubes 213, 347
Nantox project, EC-funded 270
national and intergovernmental levels of regulation 151
National Biotechnology Strategy 171
National Industrial Chemicals Notification and Assessment Scheme (NICNAS) (Australia) 249–51, 253–256
National Institute of Occupational Safety (NIOSH) (US) 189, 192, 197–9
National Metrology Institute 275, 337–8, 340
National Nanotechnology Initiative (NNI) (US) 192, 239, 356, 366
National Nanotechnology Strategy Taskforce (NNST) (Australia) 166, 167, 247–9
national reaction to gene technology 169
National Resources Defense Council (NRDC), resignation 195
national workplace exposure standards 135
negative harmonization 292, 298–9
Netherlands, and European legislation 272, 273, 276
Netherlands R&D 73
network technologies 37
neuroscience 49
neurotoxicity 140
new substances 194, 218, 219, 222, 232
‘new’ or ‘existing’ chemical 327
nomenclature 277, 280, 344, 346, 355
non-governmental organizations (NGOs) 102, 125, 158, 207, 305
non-tariff barriers to trade 321, 323, 326
North American Free Trade Agreement (NAFTA) 321–2
North-South divide 97, 99–100, 102
nutritional delivery systems 253
objects, constructed or natural 277
occupational hazards 138
Occupational Safe Practices 348
occupation health and safety (OH&S) 15, 16, 248, 345
Office of Combination Products 197
Office of the Gene Technology Regulator (OGTR), (Australia) 137
online gambling case, US 295
open communication 332
opportunities and risks 78
optical properties 4
Organisation for Economic Co-operation and Development (OECD) 235
chemicals workshop 328
membership 322
and safety aspects 321–32
oxidative damage to cells 213
ozone pollution 152, 300, 305
pacemakers, heart 57
paper manufacturing and plastics 214, 225
Parkinson’s Disease 58
participating countries, needs 348, 349
particles ultrafine 134, 204, 224
Patent and Trademark Office (US PTO) 366–7
patents 277–8, 280, 356
granting 60–61
nanotechnology-related 366, 367
patient organizations, input 268
peace movements 274
penetration of cellular barriers 212
performance-based regulation 155, 156
performance indicators 121, 131
permeation of skin 257
personal information databases on
Internet 57
personal injury insurance 149
personal privacy, loss of 52, 169
personal protective equipment 195
pesticides 152, 191, 193, 252, 322–3
pharmaceutical sector 123, 268, 367–72
regulation 195, 354
physical and chemical characteristics
139, 341
physical standards 339–40
pigments 214
plant protection products 214, 225, 231
plastics 214, 277
political class, lack of trust in 38
political impact of technology 29
political Left and Right 161
political system in US, against action
208
pollutants 152, 222
pollution from nanotechnology 201
polyethylene 277
polymer composites 212
population, world 33, 91
‘positive’ and ‘negative’ harmonization,
definitions 293, 299–301, 316–17
potential risks from nanotechnologies
234
power and control 61, 89, 100, 101
precautionary principle 50, 55, 364,
376
in European Union 267, 268
predictions of nanotechnology 50, 53,
54
premanufacture notice (PMN) 200
prescriptive regulation 150, 155
primary mode of action 197
privacy 15, 16, 55–7, 78–82, 168, 388
loss of 62, 79
private forms of regulation 155
problems and solutions 112, 155
process-related regulatory distinctions
293–4
production processes and methods
294
products 103, 215–216, 223
distinctions 296
liability regulation 96
life cycle regulation 17
safety 15, 16, 96
standards 290, 304
profit 88, 94–6, 104, 390
Prohibition of Human Cloning Act
(Cth) (Australia) 2002 240–41
properties
of known materials, change 35
of nanotechnologies 35, 232, 233
protection of man and environment
323
protectionism 290, 299, 316
protocols for containment and testing
345
public
acceptance of 70, 71, 78–9, 279
backlash from 81, 82
confidence of 209, 236
engagement of, in science-related
issues 102, 129
participation component 206, 210
public dialogue 69, 74, 126, 235
public interest 19, 111–29, 181
public involvement in nanotechnology
74, 181
public morals 295, 310, 312, 313
public policy 6, 16, 21, 112–13, 118–19
public-private sector 362, 364
public servants, role of 114, 115
public trust and nanotechnology 69
pulmonary disease 134, 138
purposes for evaluation 120–21
pyramid of regulatory strategies 14, 15
quality improvement 346
quantum dots 140, 144, 212, 333–4,
343
R&D see research and development
radiation 152
radio frequency identification tags
(RFIDs) 56
radiographers 141
raw materials 168
REACH see Registration, Evaluation
and Authorisation of Chemicals
recycling 231, 249
<table>
<thead>
<tr>
<th>Entry</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>registration schemes</td>
<td>249</td>
</tr>
<tr>
<td>Registration, Evaluation and Authorisation of Chemicals</td>
<td>218–19, 267, 271, 291</td>
</tr>
<tr>
<td>Regulation (REACH) (EU)</td>
<td></td>
</tr>
<tr>
<td>regulation</td>
<td>8, 62, 78, 116–18, 345</td>
</tr>
<tr>
<td>absence of 212</td>
<td></td>
</tr>
<tr>
<td>and control 79</td>
<td></td>
</tr>
<tr>
<td>formal, US 193, 207</td>
<td></td>
</tr>
<tr>
<td>gaps 113, 213, 214, 232, 256</td>
<td></td>
</tr>
<tr>
<td>in Germany 272–3</td>
<td></td>
</tr>
<tr>
<td>mandatory or voluntary 195</td>
<td></td>
</tr>
<tr>
<td>and risk society 149–163, 392–3</td>
<td></td>
</tr>
<tr>
<td>nanotechnologies 14–19, 96, 137, 267, 289–96, 353–76</td>
<td></td>
</tr>
<tr>
<td>on products and applications 224</td>
<td></td>
</tr>
<tr>
<td>research 18–19</td>
<td></td>
</tr>
<tr>
<td>regulatory action 103, 118–19, 241</td>
<td></td>
</tr>
<tr>
<td>difficulties in US 194</td>
<td></td>
</tr>
<tr>
<td>in Europe 265–81</td>
<td></td>
</tr>
<tr>
<td>guidance 145</td>
<td></td>
</tr>
<tr>
<td>and measurement uncertainty 343</td>
<td></td>
</tr>
<tr>
<td>measures under GATT 291–2</td>
<td></td>
</tr>
<tr>
<td>regulatory authorities, existing or new 189</td>
<td></td>
</tr>
<tr>
<td>‘regulatory failure’ in UK 129</td>
<td></td>
</tr>
<tr>
<td>regulatory framework 8, 204, 247, 272</td>
<td></td>
</tr>
<tr>
<td>absence of 353, 354</td>
<td></td>
</tr>
<tr>
<td>and nonparticles 135–7</td>
<td></td>
</tr>
<tr>
<td>regulatory regimes 119–23</td>
<td></td>
</tr>
<tr>
<td>regulatory schemes on nanotechnology, Australia 179–81</td>
<td></td>
</tr>
<tr>
<td>reliability of new applications 168</td>
<td></td>
</tr>
<tr>
<td>religious authority, absence of 37</td>
<td></td>
</tr>
<tr>
<td>religious considerations, Australia 175, 176, 178</td>
<td></td>
</tr>
<tr>
<td>reports, detailed analysis 75</td>
<td></td>
</tr>
<tr>
<td>reproductive technologies 240</td>
<td></td>
</tr>
<tr>
<td>research and development (R&amp;D) activities 219–22, 227, 249, 274, 353, 354</td>
<td></td>
</tr>
<tr>
<td>research efforts on nanotechnologies in UK 234</td>
<td></td>
</tr>
<tr>
<td>research in Australia 176</td>
<td></td>
</tr>
<tr>
<td>research into public attitudes 125</td>
<td></td>
</tr>
<tr>
<td>research projects, European Commission 365</td>
<td></td>
</tr>
<tr>
<td>research, pure and applied 62</td>
<td></td>
</tr>
<tr>
<td>resource efficiency 81</td>
<td></td>
</tr>
<tr>
<td>resource-pooling 329</td>
<td></td>
</tr>
<tr>
<td>respiratory illness cases, Germany 274</td>
<td></td>
</tr>
<tr>
<td>respirocyte 58</td>
<td></td>
</tr>
<tr>
<td>responsibility, acknowledgement of 115</td>
<td></td>
</tr>
<tr>
<td>responsive regulation 151, 154–60</td>
<td></td>
</tr>
<tr>
<td>rewards 150</td>
<td></td>
</tr>
<tr>
<td>rhetorical use of nanotechnology 13</td>
<td></td>
</tr>
<tr>
<td>rich and poor divides 89</td>
<td></td>
</tr>
<tr>
<td>right of access, and status 93</td>
<td></td>
</tr>
<tr>
<td>rights and political equality 93</td>
<td></td>
</tr>
<tr>
<td>risk analysis 150</td>
<td></td>
</tr>
<tr>
<td>risk assessment 136, 218, 234, 330–31, 360</td>
<td></td>
</tr>
<tr>
<td>formalized 135</td>
<td></td>
</tr>
<tr>
<td>frameworks 137</td>
<td></td>
</tr>
<tr>
<td>in Germany 273</td>
<td></td>
</tr>
<tr>
<td>OECD guidance on 326</td>
<td></td>
</tr>
<tr>
<td>tools 345</td>
<td></td>
</tr>
<tr>
<td>risk management 138, 139, 149, 236, 267, 321</td>
<td></td>
</tr>
<tr>
<td>failure costs 153</td>
<td></td>
</tr>
<tr>
<td>risks 5, 68, 70, 193</td>
<td></td>
</tr>
<tr>
<td>and benefits 50, 74, 75, 82, 83</td>
<td></td>
</tr>
<tr>
<td>characterization 138, 139, 144–5</td>
<td></td>
</tr>
<tr>
<td>EU research on 269–70</td>
<td></td>
</tr>
<tr>
<td>of genetic engineering 124</td>
<td></td>
</tr>
<tr>
<td>to human health 201</td>
<td></td>
</tr>
<tr>
<td>of nanotechnology and nanoparticles 9, 73</td>
<td></td>
</tr>
<tr>
<td>and society 151–4, 392–3</td>
<td></td>
</tr>
<tr>
<td>substantial or significant 208</td>
<td></td>
</tr>
<tr>
<td>of sunscreens 257</td>
<td></td>
</tr>
<tr>
<td>unknown 201</td>
<td></td>
</tr>
<tr>
<td>risk uncertainty 160, 161</td>
<td></td>
</tr>
<tr>
<td>River Basin Management Plans 233</td>
<td></td>
</tr>
<tr>
<td>Royal Society and Royal Academy of Engineering (RS-RAE) 213</td>
<td></td>
</tr>
<tr>
<td>on metrology 342</td>
<td></td>
</tr>
<tr>
<td>review 234</td>
<td></td>
</tr>
<tr>
<td>rubber producers 61</td>
<td></td>
</tr>
<tr>
<td>rulemaking, ‘ossification’ in US 203</td>
<td></td>
</tr>
<tr>
<td>safeguards on public morals 313, 314</td>
<td></td>
</tr>
<tr>
<td>safe handling 348</td>
<td></td>
</tr>
<tr>
<td>safety 152, 268, 271, 321</td>
<td></td>
</tr>
<tr>
<td>assessments, unambiguous 320</td>
<td></td>
</tr>
<tr>
<td>of nanotechnologies 293</td>
<td></td>
</tr>
<tr>
<td>parameters 327</td>
<td></td>
</tr>
<tr>
<td>of workers and consumers 274</td>
<td></td>
</tr>
<tr>
<td>safety data, paucity of 259</td>
<td></td>
</tr>
</tbody>
</table>
Index

Safety of Manufactured Nanomaterials, OECD 363
Sanitary and Phytosanitary Measures (SPS Agreement) 294, 295, 308–10
scanning probe microscopy 13
scepticism of scientific predictions 9
science 94, 95, 116, 325
and identification of risk 289
and politics in post-modern technologies 37
and the public 69, 124, 181
and pure knowledge 31
science fiction, nanotechnology as 5, 113, 241, 267, 267
scientific experts, distrust in 126
scientific knowledge 214
lack of 214, 233, 234, 344
scientific research
in Australia 241–2
control of 63
scientific revolution 335–6
scientific risks 303, 393
scientific uncertainty 222, 241, 258, 293
scientists 63, 273
scope of IPPC Directive 227
sea mammals, protection measures 287
sea turtles, protection 306
securities analysts 158
security 168
self-interest 128, 370, 373
self-regulation 15, 155, 157, 158
self-replication, risks 116
service regulation 157
severity of problems of technology 151
sewerage 231
safe disposing 348
shrimps 306
side effects, unknown 68, 71–2
silicates 134
‘single market’ for pharmaceutical products 372
SI unit see International System of Units
skin
absorption through 144
products 276, 257
tissue, damage to 257
smart dust 56
smoke pollution 230
soap and shampoo 276
social aspects 68, 71, 74–9, 344
social benefits 3, 71, 341
social cohesion in EU 298
social impact 20, 29, 35, 270
social justice and injustice 60–63, 388
social meaning of nanotechnology 34–6, 44, 387
social science 44, 63, 73, 362
and new technologies 7
society, purpose and direction 168
socio-economic impacts 168
socio-ethical research 269–70
socio-legal concerns 166–84
soft regulatory frameworks 16, 372
software copying 51
solubilization 140
solutions known 155
Southeast Asia 90–91, 95
space travel 67
specific applications 83
sporting goods 4
spray painting of cars 294
stain-resistance 35, 67
stakeholder dialogue 16, 73–4, 125, 206–7, 210, 332
standardization 234, 268, 274–6, 344–5
standard protocols 331
standard regulation 157
standards
anticipatory 348
differing, in EU Member States 297
for nanotechnology 333–51
national and international 275
Standards Development Organization (SDO) 349
state
as consumer of drugs 370
as health policy maker 370
as regulator of drugs 149, 151, 158, 370
statistical studies of panel data 122
statutes, pre-existing 191, 192, 200
stem cell research 123, 240
stewardship programs on pollution, US 194, 195
strokes, relief of 58
‘subjective’ sources of risk assessment 154
substances, ‘new’ 194
sunscreen 5, 35, 67, 256–8, 270
zinc oxide 144
superannuation funds 166
supranational regulation 160
surface area, greater for nanoparticles 219
surgical methods of abortion 176, 177
sustainable energy 71
sweatshops in developing countries 287
Swiss Federal Office of Environment and Public Health 272
Swiss Reinsurance Company 277, 362
symbolic significance 41–2
synthetic nanoparticles, impact 73
system-based regulation 155, 156

Taiwan Accreditation Foundation (TAF) 358
Taiwan, R&D and commercialization 365
Taniguchi, Norio, and ‘nanotechnology’ 243
target groups 277
tariffs (customs duties) 290
taxonomy of nanotechnology vocabulary 346
TBT see World Trade Organization Agreement
TC229 see International Standards Organization Technical Committee 229
Technical Barriers on Trade (TBT) Agreement 289, 290–91, 294–5
Technical Committee on Nanotechnology 350
technical standardization 355
techno-animism 43, 44
technology 31, 73, 268, 386, 387
assessment in Netherlands 73
control 63
conventional 268
development 150, 151
in Belgium 273
and regulation, tension 206
fast-moving 204
as mixed blessing 34
and risks 152
telecommunications 339
tensions, regulatory 288
terminology 344, 346, 360
terrorism 55, 154
test data development 194

Test Guidelines (OECD) 325
testing methods 236, 268, 274–6, 330–31, 360
test tube baby, Australia 240
textiles 214, 225
That Cigarettes case 314, 316
thalidomide, regulatory failure 267, 373
therapeutic goods 4, 256–9
nanomaterials in 136
regulation 135, 175–7
Therapeutic Goods Administration (TGA) (Australia) 175–7, 251
think tanks 119
third party liability insurance 149, 155
third-party regulation 155–8
time and space, mastering 37
tissue culture 140
titanium oxide 144
and free radical formation 257
tolerance of violence, moral risk 152
tolerance zone of measurement 343
tools that perform actions 43
‘top-down’ approach for standards 349
TOXEL standards, toxics in polyethylene 277
toxic dust 126, 245, 246
toxicity 71, 139, 233
and eco-toxicity 330
potential 80, 197
testing, funding for 207
toxicokinetics 139
toxicological data for nanoparticles 256
toxicological properties 136
toxicology testing 348
Toxic Substances Control Act (TSCA) (US) 150, 193, 200
Trade Effluents Regulations 1989 231
Trade Related Intellectual Property Rights (TRIPS) Agreement 299, 369, 372
trade unions 38, 323, 332
trading interests of other members 293
transnational corporations 372, 373, 376
NGOs, involvement 364
pharmaceutical companies 370
Index

transparency procedures 300
transport 225, 271
TRIPS Agreement see Trade Related Intellectual Property Rights
Tuna/Dolphin case 294, 296, 297
panels 304–5
tuna from Mexico, embargo on 304, 305
turtle conservation policies 307
Tylor, Edward Burnett (Primitive Culture) 42
‘ultra fine’ urban air particulate matter (UFPs) 138
uncertainties about risks 234
unilateral action on regulations 293
unilateral environmental activities, rejection 303
unilateral initiatives and EU member states 297
United Kingdom
failure of regulation 232, 256
government departments, and research 234, 235
nanotechnology developments 212–37
Office of Science and Innovation (OSI) 235
RS-RAE 272
voluntary reporting scheme 234–5
United States
Clean Air Act 305–6
Environmental Protection Agency (EPA) 192–5, 302, 366
Gasoline Ruling 305–6
online gambling 310–14
public consultations 126, 373
Shrimp/Turtle case 306–7
statutes, inadequate 208
units and quantities 334–5
‘upstream engagement’ process, UK 129
urban air pollution 144
urban waste water treatment 231
Uruguay Round 290, 299, 369
user needs in a standard 349
UV sunscreen protection 5
vacuum, power of 31
venture capital 166
verification requirements 157
veterinary chemicals 135, 252
veterinary medicines 214
vision enhanced 59
volume of nanomaterials 139–40
voluntary agreements 301–2
at Community level 302
environmental policy and industry 302
at national policy level (EU) 302
voluntary approach to regulation, US prefers 156, 157, 366
risks of 207–8
Voluntary Reporting Scheme (VRS) 74
voluntary stewardship 194, 195, 207
voter turnout, decline of 38
war and poor intelligence 122
warfare and nanotechnology 94
waste
hazardous and solid 193
practices, sound 195
sector 302
shipment 297
treatment 231–2
Water Framework Directive (WFD) (EU) 230, 231, 233
water pollution 152, 193, 230
wealth creation and distribution 96, 213
weapons 122, 169, 214, 225
chemical, biological, nuclear 103–4
weapons of mass destruction 274
well-being as a benefit 98
winners and losers 60
workers
displacement 168
exposure to toxic dust 143, 248
training 195
workplace exposure to toxic dust 246
Work Programmes on Manufactures Nanomaterials 332
work sharing 323
World Health organization (WHO) 140
world hunger 7
World Intellectual Property Organization (WIPO) 369
Index

world metrology 336
World Summit on the Information Society 69
World Trade Organization (WTO) 104, 369
agreements 291–2
Appellate Body 299
creation 290
deficiency and regulatory challenges 291–3
dispute settlement system 288

nanotechnology regulation 287–316
negative harmonization 304
power 295–6
rules 291
Technical Barriers to Trade Agreement 304, 307
wound dressings, anti-microbial 212

zero-waste manufacturing 67
zinc oxide 144
and free radical formation 257